Tryptamine Therapeutics Limited

ASX:TYP Stock Report

Market Cap: AU$43.4m

Tryptamine Therapeutics Valuation

Is TYP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TYP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TYP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TYP's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TYP?

Key metric: As TYP is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TYP. This is calculated by dividing TYP's market cap by their current revenue.
What is TYP's PS Ratio?
PS Ratio32.7x
SalesAU$1.33m
Market CapAU$43.40m

Price to Sales Ratio vs Peers

How does TYP's PS Ratio compare to its peers?

The above table shows the PS ratio for TYP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average13.4x
ILA Island Pharmaceuticals
22.4xn/aAU$28.1m
AGN Argenica Therapeutics
29.8xn/aAU$77.5m
VIT Vitura Health
0.4xn/aAU$43.6m
ECS ECS Botanics Holdings
1.1xn/aAU$21.9m
TYP Tryptamine Therapeutics
32.7xn/aAU$43.4m

Price-To-Sales vs Peers: TYP is expensive based on its Price-To-Sales Ratio (32.7x) compared to the peer average (13.4x).

Price to Sales Ratio vs Industry

How does TYP's PS Ratio compare vs other companies in the AU Pharmaceuticals Industry?

17 CompaniesPrice / SalesEstimated GrowthMarket Cap
MYX Mayne Pharma Group
1x9.3%US$241.07m
PBP Probiotec
1.1x6.7%US$160.13m
VLS Vita Life Sciences
1.3xn/aUS$63.15m
MVP Medical Developments International
1.4x14.4%US$28.54m
TYP 32.7xIndustry Avg. 4.3xNo. of Companies17PS01224364860+
17 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TYP is expensive based on its Price-To-Sales Ratio (32.7x) compared to the Australian Pharmaceuticals industry average (4.3x).

Price to Sales Ratio vs Fair Ratio

What is TYP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TYP PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio32.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate TYP's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 08:24
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tryptamine Therapeutics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael HigginsLadenburg Thalmann & Company